“…Effect of Acarbose on hepatic gene expression. Hepatic gene expression of (A)Fgf21 (effect of treatment: F1.16 = 15.16, p< 0.0012, η 2 = 2.75%; of diet: F1 16. = 518.99, p < 0.0001, η 2 = 94.33%), (B) Cyp2e1 (effect of treatment: F1.16 = 8.92, p< 0.0087, η 2 = 24.97%; of diet: F1.16 = 4.58, p < 0.0480, η 2 = 12.84%; and treatment x diet F1.16 =6.20, p < 0.0001, η 2 = 17.37%) (C) Il1b(effect of treatment: F1.20 = 10.44, p< 0.0041, η 2 = 20.29%; of diet: F1.20 = 11.62, p < 0.0028, η 2 = 22.59%; and treatment x diet F1.20 = 9.38, p < 0.0061, η 2 = 18.24%), (D) Il6 (effect of treatment: F1.16 = 16.44, p< 0.0009, η 2 = 27.41%; of diet: F1.16 = 11.25 p < 0.0040, η 2 = 18.76%; and treatment x diet F1.16 = 16.27, p < 0.0009, η 2 = 27.13%), (E) G6pc (effect of treatment: F1.16 = 10.39, p< 0.0053, η 2 = 14.87%; of diet: F1.16 = 18.81 p < 0.0005, η 2 = 25.90%; and treatment x diet F1.16 = 24.72, p < 0.0001, η 2 =35.35%), (F) Ppck (effect of treatment: F1.21 = 25.64, p< 0.0001, η 2 = 26.17%; of diet: F1.21 = 21.20, p < 0.0001, η 2 = 21.64 %; and treatment x diet F1.21 = 30.14, p < 0.0001, η 2 = 30.75%), (G) Srebp1c (effect of treatment: F1.21 = 6.08, p< 0.0223, η 2 = 17.59% and treatment x diet F1.21 = 4.89, p < 0.0381, η 2 = 14.16%), (H) Srepb2 (effect of treatment: F1.21 = 8.68, p< 0.0077, η 2 = 15.52%; of diet: F1.21 = 10.31, p < 0.0038, η 2 = 21.27%; and treatment x diet F1.21 = 9.33, p < 0.0060, η 2 = 18.83%), (I) Abca1 (effect of treatment: F1.21 = 7.35, p< 0.0130, η 2 = 14.51%; of diet: F1.21 = 9.97, p < 0.0047, η 2 = 19.69%; and treatment x diet F1.21 = 12.34, p < 0.0020, η 2 = 24.35%), (J) Cpt1 (effect of treatment: F1.21 = 10.37 p< 0.0041, η 2 = 21.66%; of diet: F1.21 = 7.56, p < 0.0119, η 2 = 15.80%; and treatment x diet F1.21 = 8.95, p < 0.0069, η 2 = 18.68%), and (K) Acc (effect of treatment: F1.21 = 15.55 p< 0.0007, η 2 = 28.84%; of diet: F1.21 = 6.99, p < 0.0151, η 2 = 12.98%; and treatment x diet F1.21 = 10.36, p < 0.0041, η 2 = 19.22%), (n = 7-5 per each group).…”